newsfilter
← Latest News
Business Wire·

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million Reported results